Iron overload, public health, and genetics: Evaluating the evidence for hemochromatosis screening

Annals of Internal Medicine

Volumn 129, Issue 11, 1998, Pages 971-979

  Cogswell, Mary E ^a   McDonnell, Sharon M ^a   Khoury, Muin J ^a   Franks, Adele L ^a   Burke, Wylie ^b   Brittenham, Gary ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFERRIN;

ARTICLE; DIAGNOSTIC ACCURACY; GENE MUTATION; GENETIC SCREENING; HEALTH ECONOMICS; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; LABORATORY TEST; LIVER BIOPSY; MASS SCREENING; MORBIDITY; MORTALITY; PHLEBOTOMY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; SCREENING TEST; STANDARDIZATION; TREATMENT OUTCOME;

EID: 0032401720     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-11_part_2-199812011-00008     Document Type: Article

References (80)

1. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice Guideline Development Task Force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta. 1996;245:139-200.
2. Balan V, Baldus W, Fairbanks V, Michels V, Burritt M, Klee G. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology. 1994;107:453-9.
3. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology. 1995;109:177-88.
4. Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology. 1995;22:1720-7.
5. Baer DM, Simons JL, Staples RL, Rumore GJ, Morton CJ. Hemochromatosis screening in asymptomatic ambulatory men 30 years and older. Am J Med. 1995;98:464-8.
6. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994; 154:769-76.
7. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med. 1993;328:1616-20.
8. Buffone GJ, Beck JR. Cost-effectiveness analysis for evaluation of screening programs: hereditary hemochromatosis. Clin Chem. 1994;40:1631-6.
9. Haddow JE, Ledue TB. Preventing manifestations of hereditary haemochromatosis through population based screening. J Med Screen. 1994;1:16-21.
10. Lederle FA. Screening for hemochromatosis? J Gen Intern Med. 1989;4:61-3.
11. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: a unifying analysis of published intervention trials. J Med Screen. 1996;3:178-84.
12. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
13. Mercier B, Mura C, Ferec C. Putting a hold on "HLA-H" [Letter]. Nat Genet. 1997;15:234.
14. Franks AL, Marks JS. Introduction to supplement on iron overload, public health, and genetics. Ann Intern Med. 1998;129:923-4.
15. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 2d ed. Baltimore, MD: Williams & Wilkins; 1996:231-46.
16. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of hemochromatosis. Ann Intern Med. 1998;129:925-31.
17. Simon M, Bourel M, Genetet B, Fauchet R. Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med. 1977;297:1017-21.
18. Burke W, Thomson E, Khoury MJ, McDonnell SM, Press N, Adams PC, et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA. 1998;280:172-8.
19. Carella M, D'Ambrosio L, Totaro A, Grifa A, Valentino MA, Piperno A, et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet. 1997;60:828-32.
20. Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis. 1996; 22:187-94.
21. Jouanolle AM, Gandon G, Jezequel P, Blayau M, Campion ML, Yaouanq J, et al. Haemochromatosis and HLA-H [Letter]. Nat Genet. 1996;14:251-2.
22. Barton JC, Shin WW, Sawada-Hirai R, Acton RT, Harmon L, Rivers C, et al. Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis. 1997;23:135-45.
23. Borot N, Roth M, Malfroy L, Demangel C, Vinel JP, Pascal JP, et al. Mutations in the MHC class 1-like candidate gene for hemochromatosis in French patients. Immunogenetics. 1997;45;320-4.
24. Beutler E, Gelbart T. HLA-H mutations in the Ashkenazi Jewish population. Blood Cells Mol Dis. 1997;23:95-8.
25. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34: 275-8.
26. Phatak PD, Sham RL, Raubertas RF, Dunnigan K, O'Leary MT, Braggins C, et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med. 1998;129:954-61.
27. McDonnell SM, Phatak PD, Felliti V, Hover A, McLaren GD. Screening for hemochromatosis in primary care settings. Ann Intern Med. 1998;129: 962-70.
28. Iron overload disorders among Hispanics - San Diego, California, 1995. MMWR Morb Mortal Wkly Rep. 1996;45:991-3.
29. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med. 1988;318:1355-62.
30. Niederau C, Niederau CM, Lange S, Littauer A, Abdel-Jalil N, Maurer M, et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med. 1998;128: 337-45.
31. Hsieh CL, Sutton HE. Mitochondrial and nuclear variants in a U.S. black population: origins of a hybrid population. Ann Hum Genet. 1992;56:105-12.
32. Chakraborty R, Kamboh MI, Nwankwo M, Ferrell RE. Caucasian genes in American blacks: new data. Am J Hum Genet. 1992;50:145-55.
33. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107-19.
34. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology. 1992;15:655-9.
35. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-62.
36. Bradley LA, Haddow JE, Palomaki GE. Population screening for hemochromatosis: expectations based on a study of relatives of symptomatic probands. J Med Screen. 1996;3:171-7.
37. Launois B, Chauvin J, Machado ML, Bourdonnec P, Campion JP, Bardaxoglou E. [Surgical treatment of hepatocarcinoma in cirrhosis.] Ann Gastroenterol Hepatol (Paris). 1996;32:35-9.
38. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer. 1996; 77:2217-22.
39. Bellantani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, et al. Prevalence of chronic liver disease in the general population of Northern Italy: the Dionysos Study. Hepatology. 1994;20:1442-9.
40. Bell H, Skinningsrud A, Raknerud N, Try K. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases. J Intern Med. 1994;236:315-22.
41. Piperno A, D'Alba R, Fargion S, Roffi L, Sampietro M, Parma S, et al. Liver iron concentration in chronic viral hepatitis: a study of 98 patients. Eur J Gasterenterol Hepatol. 1995;7:1203-8.
42. Olynyk J, Half P, Ahern M, Kwiatek R, Mackinnon M. Screening for genetic haemochromatosis in a rheumatology clinic. Aust N Z J Med. 1994; 24:588-9.
43. Rosenqvist M, Hultcrantz R. Prevalence of a haemochromatosis among men with clinically significant bradyarrhythmias. Eur Heart J. 1989;10:473-8.
44. Conte D, Manachino D, Colli A, Guala A, Aimo G, Andreoletti M, et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med. 1998;128:370-3.
45. George DK, Evans RM, Crofton RW, Gunn IR. Testing for haemochromatosis in the diabetic clinic. Ann Clin Biochem. 1995;32:521-6.
46. Manachino O, Andrea G, Antonio O, Renato M. Hemochromatosis and diabetes [Letter]. Mayo Clin Proc. 1994;69:913-4.
47. Kaye TB, Quay AT, Simonson DC. Non-insulin-dependent diabetes mellitus and elevated serum ferritin level. J Diabetes Complications. 1993;7:246-9.
48. Singh BM, Grunewald RA, Press M, Muller BR, Wise PH. Prevalence of haemochromatosis amongst patients with diabetes mellitus. Diabet Med. 1992;9:730-1.
49. Czink E, Tamas G. Screening for idiopathic hemochromatosis among diabetic patients [Letter]. Diabetes Care. 1991;14:929-30.
50. O'Brien T, Barrett B, Murray DM, Dinneen S, O'Sullivan DJ. Usefulness of biochemical screening of diabetic patients for hemochromatosis. Diabetes Care. 1990;13:532-4.
51. Phelps G, Chapman I, Hall P, Braund W, Mackinnon M. Prevalence of genetic haemochromatosis among diabetic patients. Lancet. 1989;2:233-4.
52. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med. 1998;129:946-53.
53. Cartwright GE. Hemochromatosis. In: Wintrobe MM, ed. Harrison's Principles of Internal Medicine. 7th ed. New York: McGraw-Hill; 1974:618-9.
54. Gayle CB. Hemochromatosis and dietary iron supplementation: implications from US mortality, morbidity, and health survey data. J Am Diet Assoc. 1992; 92:208-12.
55. Barton JC, McDonnell SM, Adams PC, Brissot P, Powell LW, Edwards CQ, et al. Management of hemochromatosis, Ann Intern Med. 1998;129: 932-9.
56. Adams PC. Factors affecting the rate of iron mobilization during venesection therapy for genetic hemochromatosis. Am J Hematol. 1998;58:16-9.
57. Zhou XY, Tomatsu S, Fleming RE, Parkkila S, Waheed A, Jiang J, et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA. 1998;95:2492-7.
58. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med. 1976;45:611-23.
59. Finch SC, Finch CA. Idiopathic hemochromatosis: an iron storage disease. Medicine (Baltimore). 1955;34:381-430.
60. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology. 1991;101:368-72.
61. Powell LW. Changing concepts in haemochromatosis. Postgrad Med J. 1970;46:200-9.
62. Milder MS, Cook JD, Stray S, Finch CA. Idiopathic hemochromatosis, an interim report. Medicine (Baltimore). 1980;59:34-49.
63. Looker AC, Johnson CL. Prevalence of elevated serum transferrin saturation in adults in the United States. Ann Intern Med. 1998;129:940-5.
64. Bassett ML, Halliday JW, Bryant S, Dent O, Powell LW. Screening for hemochromatosis. Ann N Y Acad Sci. 1988;526:274-89.
65. Lilienfeld DE, Stolley PD. Foundations of Epidemiology. 3d ed. New York: Oxford Univ Pr; 1994:118-23.
66. Milman N. Iron status markers in hereditary haemochromatosis: distinction between individuals being homozygous and heterozygous for the haemochromatosis allele. Eur J Haematol. 1991;47:292-8.
67. Beaton GH, Corey PN, Steele C. Conceptual and methodological issues regarding the epidemiology of iron deficiency and their implications for studies of the functional consequences of iron deficiency. Am J Clin Nutr. 1989; 50:575-85.
68. Bookstein L, Gidding SS, Donovan M, Smith FA. Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Impact on the assessment of risk according to the National Cholesterol Education Program guidelines. Arch Intern Med. 1990;50:1653-7.
69. Holtzman NA, Watson MS, eds. Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing of the National Institutes of Health. Baltimore: Johns Hopkins Univ Pr; 1998.
70. Sackett DL, Haynes RB, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston: Little, Brown; 1985.
71. Tobkes AI, Nord HJ. Liver biopsy: review of methodology and complications. Dig Dis. 1995;13:267-74.
72. Alper JS, Geller LN, Barash Cl, Billings PR, Laden V, Natowicz MR. Genetic discrimination and screening for hemochromatosis. J Public Health Policy. 1994;15:345-58.
73. Guyer MS, Collins FS. How is the Human Genome Project doing, and what have we learned so far? Proc Natl Acad Sci U S A. 1995;92:10841-8.
74. Hubbard R, Lewontin RC. Pitfalls of genetic testing. N Engl J Med. 1996; 334:1192-4.
75. Garver KL, Garver B. The Human Genome Project and eugenic concerns. Am J Hum Genet. 1994;54:148-58.
76. Institute of Medicine. Assessing Genetic Risks: Implications for Health and Social Policy. Washington, DC: National Academy Pr; 1994.
77. Adams PC, Valberg CS. Screening of blood donors for hereditary hemochromatosis: decision analysis comparing genotyping to phenotyping [Abstract]. Gastroenterology. 1997;112:A1207.
78. Wetterhall SF, Cogswell ME, Kowdley KV. Public health surveillance for hereditary hemochromatosis. Ann Intern Med. 1998;129:980-6.
79. Grindon AJ. Blood donation from patients with hemochromatosis. JAMA. 1993;270:880.
80. Brittenham GM, Franks AL, Rickles FR. Research priorities in hereditary hemochromatosis. Ann Intern Med. 1998;129:993-6.